Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access

The FDA's approval of Johnson & Johnson’s Icotyde (icotrokinra) on March 17, 2026 (announced March 18) marks a major technological and clinical milestone in dermatology. As the first-in-class targeted oral peptide that inhibits the interleukin-23 (IL-23) receptor, Icotyde brings "biologic-like" skin clearance to a once-daily pill. This approval is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.

For market-access, payer, and prescribing teams, Icotyde’s entry disrupts a mature but highly contested therapeutic category. It directly challenges both established injectable IL-23 biologics—such as Skyrizi (risankizumab), Tremfya (guselkumab), Ilumya (tildrakizumab), and Omvoh (mirikizumab)—and the leading oral competitor, Bristol Myers Squibb’s TYK2 inhibitor Sotyktu (deucravacitinib).

This access brief details the clinical data supporting the approval, provides a structural comparison against current therapies, analyzes early commercial prior-authorization (PA) gates, and outlines the launch parameters access leads must navigate.

---

Short answer: what access teams need to know

• Approval Date: March 17, 2026, as novel drug approval #7 of the year.
• Mechanism & Dosing: First oral targeted peptide blocking the IL-23 receptor. Dosed as 200 mg orally once daily, taken on an empty stomach with a 30-minute fast before eating.
• Indication: Moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
• Clinical Efficacy (ICONIC-ADVANCE 1 & 2): Approximately 70% of patients achieved an Investigator's Global Assessment (IGA) score of 0 or 1 (clear or almost clear skin) and approximately 55% achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) at week 16. It demonstrated statistical superiority over the oral active comparator deucravacitinib (Sotyktu) on co-primary endpoints.
• Early Payer Gating: Published commercial policies (such as UnitedHealthcare's medical necessity policy PA-Med-Nec-Icotyde) gate Icotyde behind a documented 3-month trial failure of methotrexate OR the prior use of a systemic targeted immunomodulator (e.g., adalimumab, Skyrizi, Tremfya, Sotyktu, Otezla).
• Patient Support (withMe): The manufacturer is launching the "withMe" program, offering eligible commercially insured patients a free-drug bridge for up to 3 years if coverage is delayed more than 5 business days or denied.

---

What is Icotyde (icotrokinra) and why is it a new class?

To understand Icotyde's position, it is necessary to distinguish it from small-molecule oral therapies and monoclonal antibody biologics. Traditionally, systemic psoriasis therapies have been divided into:

1. Oral Small Molecules: Agents like methotrexate, cyclosporine, and apremilast (Otezla) or deucravacitinib (Sotyktu). While convenient, small molecules like Otezla typically yield lower skin-clearance rates (e.g., PASI 90 rates of ~20% at week 16) or, in the case of Sotyktu, require safety warnings related to laboratory abnormalities, infections, and class-related concerns.
2. Injectable Monoclonal Antibodies (Biologics): Highly targeted proteins that block cytokines like IL-17 or IL-23. Injectable IL-23 inhibitors (Skyrizi, Tremfya) have become the gold standard for efficacy, delivering PASI 90 rates of 70% to 80% at week 16, but they require subcutaneous injections and complex cold-chain distribution.

Icotyde (icotrokinra) is a targeted oral peptide. It is structurally designed to mimic the binding characteristics of a monoclonal antibody but is engineered as a stable, synthetic peptide that can survive the gastrointestinal tract and bind directly to the IL-23 receptor (IL-23R). By blocking IL-23R, it prevents the binding of the IL-23 cytokine, thereby downregulating the inflammatory cascade responsible for plaque formation.

Peptide Engineering and Oral Delivery

Peptides are normally degraded by proteolytic enzymes in the gastrointestinal tract and absorbed poorly, which is why IL-23-targeting agents to date have been injectable monoclonal antibodies. Icotyde was engineered as a stable synthetic peptide that survives the GI tract and binds the IL-23 receptor after oral administration — the property that makes it the first targeted oral IL-23R therapeutic.

The FDA-approved label imposes a specific administration condition tied to this oral peptide delivery: Icotyde must be taken on an empty stomach. Patients take the 200 mg tablet in the morning with water, at least 30 minutes before any food intake, and must fast for at least 30 minutes after dosing.

This fasting window is a critical operational consideration for patient adherence. Access teams should note that real-world compliance may be affected by this empty-stomach requirement compared to Sotyktu or Otezla, which can be taken with or without food.

---

What did the Phase 3 ICONIC-ADVANCE trials show?

The regulatory package for Icotyde was anchored by the Phase 3 clinical development program, which enrolled approximately 2,500 patients across multiple trials. The pivotal trials, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluated the efficacy and safety of once-daily oral icotrokinra in patients with moderate-to-severe plaque psoriasis (defined as a body surface area [BSA] involvement of at least 10%, an IGA score of at least 3, and a PASI score of at least 12).

Co-Primary Endpoint Results at Week 16

Both trials used two co-primary endpoints at week 16:

1. IGA 0/1 (Clear or Almost Clear Skin): The percentage of patients achieving an IGA score of 0 or 1 with at least a 2-point improvement from baseline.
2. PASI 90: The percentage of patients achieving a 90% or greater reduction in PASI score from baseline.

In both trials, once-daily icotrokinra met these endpoints with high statistical significance:

• IGA 0/1 Response: Approximately 70% of patients in the icotrokinra arm achieved clear or almost clear skin at week 16, compared to less than 10% in the placebo arm.
• PASI 90 Response: Approximately 55% of patients in the icotrokinra arm reached PASI 90 at week 16, compared to less than 5% in the placebo arm.

Head-to-Head Superiority Over Deucravacitinib (Sotyktu)

Crucially, the ICONIC-ADVANCE program featured a head-to-head active-comparator design against Bristol Myers Squibb's oral TYK2 inhibitor Sotyktu (deucravacitinib).

• On the co-primary endpoints at week 16, once-daily icotrokinra demonstrated statistical superiority over deucravacitinib. In ICONIC-ADVANCE 1, deucravacitinib achieved an IGA 0/1 rate of about 50% and a PASI 90 rate of about 30%; icotrokinra's corresponding rates of roughly 68% (IGA 0/1) and 55% (PASI 90) translated to an advantage of roughly 18 and 25 percentage points, respectively.
• Crossover Design at Week 24: The trials also featured a crossover phase. Patients originally randomized to deucravacitinib who did not achieve adequate response were crossed over to icotrokinra at week 24, resulting in a rapid increase in skin clearance. This crossover data provides strong clinical evidence for access teams seeking to define step-therapy exceptions or secondary-line oral options.

Analysis of Key Secondary Endpoints

Beyond the co-primary endpoints, icotrokinra demonstrated robust efficacy across secondary endpoints at week 16:

• Complete Skin Clearance (PASI 100): In the head-to-head comparison, approximately 31% of icotrokinra-treated patients achieved complete skin clearance (PASI 100) at week 16 — roughly two to three times the deucravacitinib rate (about 11–14%) in the same trials.
• Patient-Reported Symptom Relief: About 24% of icotrokinra-treated patients reported a symptom score of 0 on the Psoriasis Symptoms and Signs Diary (PSSD) at week 16, compared with about 9% in the deucravacitinib arm.

Pediatric and Adolescent Indication

Unlike many specialty therapies that launch with adult-only indications, Icotyde secured approval for pediatric patients 12 years of age and older weighing at least 40 kg. The adolescent data showed a clinical profile consistent with that seen in adults, with similar efficacy and safety. Given that pediatric patients and their caregivers often prefer oral medications over self-injection, this adolescent indication is a key competitive differentiator that will drive pediatric dermatology utilization.

---

Safety and Tolerability Profile

A major focus for P&T committees is safety, particularly when comparing an oral agent to established subcutaneous biologics. Monoclonal antibodies blocking IL-23 (like Skyrizi or Tremfya) have long-term safety data showing low rates of systemic adverse events and no class-related black-box warnings.

In the Phase 3 ICONIC-ADVANCE trials, icotrokinra demonstrated a safety profile that closely mirrors that of injectable IL-23 inhibitors, with excellent tolerability and low discontinuation rates:

• Common Adverse Events: In the ICONIC-ADVANCE program, the most frequently reported adverse events were nasopharyngitis and upper respiratory tract infections. Overall adverse-event rates for icotrokinra-treated patients stayed within roughly 1 percentage point of placebo through week 16, and no new safety signals were identified through week 52.
• Favorable Tolerability vs. Deucravacitinib: Through 24 weeks, adverse-event rates were numerically lower with icotrokinra than with the active comparator deucravacitinib, reinforcing the drug's "biologic-like" tolerability profile.
• No Routine Lab Monitoring: Unlike small-molecule oral agents that require baseline and periodic laboratory monitoring (for example, the lipid, liver-enzyme, and CPK checks associated with JAK inhibitors), Icotyde's clinical program did not mandate routine blood monitoring, reducing the administrative burden on clinical practices.
• Infection Risk: As with immunomodulators generally, Icotyde may increase the risk of infections including tuberculosis. Patients should be evaluated for tuberculosis and monitored for signs and symptoms of infection before and during treatment.

---

How does Icotyde compare with other psoriasis classes?

To assist formulary modeling and P&T committees, the table below compares the clinical and operational profiles of once-daily oral Icotyde, the oral TYK2 inhibitor Sotyktu, and the leading injectable IL-23 biologic Skyrizi.

Key Takeaways from the Comparison

1. Efficacy Positioning: Icotyde sits in the "sweet spot" between oral small molecules and injectable biologics. It delivers significantly higher clearance rates than Sotyktu but remains slightly below the absolute clearance rates of maintenance injectables like Skyrizi (which reaches PASI 90 rates of ~75% at week 16).
2. Safety Profile Advantage: Sotyktu’s label contains warnings for rhabdomyolysis and creatine phosphokinase (CPK) elevations, and some payers group it with JAK inhibitors (despite its selective TYK2 mechanism). As a targeted peptide, Icotyde's safety profile is clean and biologic-like, characterized primarily by localized gastrointestinal events (mild diarrhea, headache) and standard infection screening requirements, with no class-related black-box warnings.
3. Fasting Burden: The operational challenge for Icotyde is its fasting requirement, which Sotyktu and Skyrizi lack.

---

What prior-authorization criteria are commercial payers requiring?

Payer coverage for newly approved specialty drugs typically goes through a 180-day review period during which plans impose a "new-to-market block." However, because Icotyde represents a high-profile class entrant, top-tier payers are rapidly publishing their prior-authorization (PA) and medical-necessity criteria.

A review of early commercial policies, such as UnitedHealthcare’s commercial prior-authorization policy (PA-Med-Nec-Icotyde), shows that payers are placing strict gates to prevent unrestricted first-line systemic use.

Standard Prior-Authorization Requirements

To secure coverage for Icotyde under a standard commercial policy, the following clinical and administrative criteria must be met:

1. Age and Weight Verification: The patient must be at least 12 years of age and weigh at least 40 kg.
2. Diagnosis Severity: A documented diagnosis of moderate-to-severe chronic plaque psoriasis, typically defined by:
   • Body Surface Area (BSA) involvement of at least 10%, OR
   • Involvement of critical areas (such as the face, hands, feet, or genitalia) that severely impacts daily functioning.
3. Prescriber Specialty: The medication must be prescribed by, or in consultation with, a board-certified dermatologist.
4. Prior Failure of Standard Therapy (Step-Edit):
   • A documented history of an inadequate response (typically defined as a trial of at least 3 months), contraindication, or intolerance to methotrexate (or other systemic agents like cyclosporine or acitretin if methotrexate is clinically inappropriate).
   • OR, the patient must have a documented trial and failure of at least one systemic targeted immunomodulator. Payers list preferred products within their formularies, which may include adalimumab biosimilars, Skyrizi, Tremfya, Sotyktu, or Otezla.
5. Reauthorization Gating: Initial approvals are typically granted for 12 months. To secure reauthorization, the provider must document positive clinical response, defined as a significant reduction in BSA involvement or improvement in the PASI/IGA score, and the drug must not be used in combination with other systemic targeted immunomodulators (e.g., combining Icotyde with Skyrizi).

Emerging PBM Formulary Placement Scenarios

PBMs (CVS Caremark, Express Scripts, and OptumRx) are modeling their formulary placement for Icotyde across three primary scenarios:

• Scenario A: Strict Exclusion (Preferred Injectables). Under this scenario, the PBM excludes Icotyde or places it on Tier 4 (non-preferred) with a requirement that patients first try and fail two preferred injectable biologics (e.g., Skyrizi and a biosimilar adalimumab). This protects PBM rebate streams from existing biologic contracts but limits patient access to the oral option.
• Scenario B: Oral-Preferred Tiering. PBMs may create an "oral systemic tier" where Sotyktu and Icotyde are co-preferred on Tier 3. Patients must try and fail Otezla or methotrexate first, but once they qualify for an oral immunomodulator, Icotyde and Sotyktu can compete directly on clinical merit.
• Scenario C: Pediatric/Adolescent Exception. Because Skyrizi is not indicated for patients under 18 years of age with plaque psoriasis (Tremfya is approved down to age 6, but IL-23 coverage is patchy), PBMs may carve out an exception for adolescent patients. Commercially insured patients aged 12–17 may access Icotyde without needing to fail adult-only preferred injectables first.

---

How should access teams model Icotyde on price and support?

For manufacturer launch teams and PBM formulary managers, Icotyde's commercial success depends on its net cost positioning and its patient-support programs.

Wholesale Acquisition Cost (WAC) Benchmarking

At launch, Icotyde's WAC pricing is expected to be benchmarked against the oral comparator Sotyktu, which carries a WAC of $6,164.78 per 30-day supply (approximately $74,000 annually).

• If J&J prices Icotyde at a parity or modest premium to Sotyktu, it can leverage its superior head-to-head clinical efficacy to gain quick Tier 3 preferred status.
• However, if priced closer to the annual WAC of injectable biologics (Skyrizi maintenance runs approximately $91,000 annually based on WAC), payers will enforce strict step-therapy rules requiring patients to fail Sotyktu or Otezla first.

The "withMe" Patient Support Program

To mitigate the impact of commercial PA delays and high deductibles, J&J is deploying its withMe patient-support program. Two terms are operationally important for access teams:

• Co-Pay Assistance: Eligible commercially insured patients can access co-pay assistance to lower out-of-pocket costs at the pharmacy.
• The 3-Year Free Drug Bridge: For patients whose commercial insurance coverage is delayed or denied, the withMe program provides Icotyde at no cost for up to 3 years, or until their commercial plan covers the medicine. The bridge is triggered if a coverage decision is delayed more than 5 business days.

This aggressive bridge program is designed to bypass new-to-market payer blocks and build prescriber loyalty. Prescribers can write for Icotyde knowing their commercially insured patients can start therapy immediately, shifting the administrative burden of the PA appeal to the manufacturer's hub.

---

Long-Term Market Implications: Payer and Provider Perspectives

The introduction of Icotyde will reshape the commercial dynamics of the plaque psoriasis market over the next three to five years. Access teams must consider several long-term factors:

1. Rebate Erosion in the IL-23 Class

Currently, major payers maintain highly restrictive formularies dominated by a single preferred IL-23 inhibitor (typically Skyrizi), secured through deep manufacturer discounts and rebates. If Icotyde gains significant clinical traction due to its oral convenience, plans may be forced to open their formularies. This could lead to a dilution of the market share of established injectables, potentially triggering renegotiations of existing rebate contracts.

2. Specialty Pharmacy vs. Buy-and-Bill Routing

Because Icotyde is a self-administered oral tablet, it will route exclusively through the pharmacy benefit channel via specialty pharmacies. Unlike injectable biologics, which are sometimes administered in physician offices and billed under the medical benefit (buy-and-bill), Icotyde will not generate physician administration fees. Specialty pharmacies must prepare for specialized distribution workflows, including counseling patients on the mandatory 30-minute post-dose fasting window.

3. Competitor Pipeline Counter-Moves

J&J's early approval gives Icotyde a first-mover advantage as the only oral IL-23 receptor peptide. However, competitors are not standing still. Several other oral peptides and highly selective small-molecule inhibitors targeting the IL-23 pathway are currently in Phase 2 and Phase 3 development. Access teams should anticipate that the oral targeted immunology class will become crowded by 2028, necessitating a clear long-term differentiation strategy based on real-world outcomes and patient-adherence data under the fasting restriction.

---

FAQs

When was Icotyde (icotrokinra) approved and for which psoriasis population?

Icotyde was approved by the FDA on March 17, 2026. It is indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.

Is Icotyde a biologic, a TYK2 inhibitor, or a different drug class?

Icotyde is a targeted oral peptide. It is not a traditional monoclonal antibody biologic (which must be injected) and it is not a small-molecule kinase inhibitor like the TYK2 inhibitor Sotyktu. It represents a new class of oral systemic immunology agents that block the IL-23 receptor directly.

Will Icotyde be covered before a patient tries methotrexate or a biologic under typical commercial PA rules?

No. Under standard commercial payer rules (such as those published by UnitedHealthcare), patients must typically document a 3-month trial and failure of methotrexate or another systemic targeted immunomodulator before Icotyde is approved. However, the withMe support program provides a free-drug bridge for up to 3 years to ensure patients can begin treatment while their prior-authorization or appeal is processed.

What is the primary difference in dosing administration between Icotyde and Sotyktu?

Icotyde (icotrokinra) is dosed at 200 mg once daily and must be taken on an empty stomach (1 hour before or 2 hours after a meal) followed by a 30-minute fast. Sotyktu (deucravacitinib) is dosed at 6 mg once daily and can be taken with or without food, with no fasting restrictions.

Does Icotyde require regular blood tests or laboratory monitoring?

No. Unlike small-molecule JAK inhibitors or TYK2 inhibitors that require baseline and periodic blood monitoring (for lipids, liver enzymes, and CPK), Icotyde’s clinical profile does not require routine laboratory monitoring, simplifying the prescribing process.

---

Sources

• U.S. Food and Drug Administration. Novel Drug Approvals for 2026 (Icotyde | icotrokinra | Approved March 17, 2026). FDA Center for Drug Evaluation and Research. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
• Johnson & Johnson. FDA Approval of ICOTYDE (icotrokinra) Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis. J&J Press Room, March 18, 2026. https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide
• UnitedHealthcare. Icotyde (icotrokinra) Commercial Medical Necessity and Prior Authorization Policy. Policy Number: PA-Med-Nec-Icotyde. Effective July 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/h-p/PA-Med-Nec-Icotyde.pdf
• Phase 3 ICONIC-ADVANCE 1 and 2 Clinical Trial Results: Efficacy, Superiority over Deucravacitinib, and Safety of Oral Icotrokinra in Plaque Psoriasis. ClinicalTrials.gov identifiers: NCT06143878 (ICONIC-ADVANCE 1) and NCT06220604 (ICONIC-ADVANCE 2).
• Bristol Myers Squibb. Sotyktu (deucravacitinib) Prescribing Information and WAC Pricing Reference. https://www.sotyktu.com
• Strober BE, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2). Published in The Lancet, 2025. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01576-4/abstract